Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) Return on Capital Employed: 2015-2025

Historic Return on Capital Employed for Ascendis Pharma A (ASND) over the last 10 years, with Sep 2025 value amounting to -1.14%.

  • Ascendis Pharma A's Return on Capital Employed rose 275.00% to -1.14% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.14%, marking a year-over-year increase of 275.00%. This contributed to the annual value of -3.02% for FY2024, which is 66.00% down from last year.
  • Ascendis Pharma A's Return on Capital Employed amounted to -1.14% in Q3 2025, which was up 52.27% from -2.38% recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's Return on Capital Employed peaked at 5.57% during Q2 2024, and registered a low of -32.50% during Q1 2024.
  • Its 3-year average for Return on Capital Employed is -3.92%, with a median of -1.16% in 2024.
  • As far as peak fluctuations go, Ascendis Pharma A's Return on Capital Employed tumbled by 3,181bps in 2024, and later spiked by 3,111bps in 2025.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Return on Capital Employed stood at -0.44% in 2021, then declined by 14bps to -0.58% in 2022, then crashed by 331bps to -3.88% in 2023, then soared by 272bps to -1.16% in 2024, then soared by 275bps to -1.14% in 2025.
  • Its Return on Capital Employed was -1.14% in Q3 2025, compared to -2.38% in Q2 2025 and -1.40% in Q1 2025.